NEW YORK (360Dx) – Precipio said this week that its preliminary first quarter revenues rose 286 percent year over year to $712,000. The increase was driven by a restructured and expanded sales staff; a separate, dedicated sales staff for pathology services and Ice Cold PCR/Pharma projects; and the increased cross-selling of pathology services with the ICP lung cancer treatment resistance panel, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.